Genechron srl is a biotech company that operates in the medical diagnostics sector. Genechron offers molecular genetics services on genes involved in the susceptibility to the development of cancer, in the response to pharmacological therapies and in the onset of hereditary pathologies or metabolic alterations. Furthermore, it carries out qualitative and quantitative analysis of microorganisms or viral agents. A peculiar characteristic of Genechron is the ability to provide specialized scientific and diagnostic support to healthcare facilities and research institutions throughout the national territory.
Genechron was born as an innovative start-up in 2016, taking over the biotech technologies of the “Genechron laboratory” of the Ylichron company, with the aim of further developing lines of research and services in the clinical field.
Genechron has highly specialized staff who have been working in the field of molecular biology and genetics for over 10 years, and uses modern and advanced instrumental equipment.
The company avails itself of a Scientific Advisory Board made up of prominent personalities from the world of Research and Clinical Medicine.
Genechron is a company founded in 2016 to further develop the biotechnological activities undertaken within the company Ylichron Srl (ENEA spin-off) and give them a market boost. Ylichron Srl, founded in 2005, has had a strong focus on the application of high performance computing (HPC) techniques in research and the industrial sector. In 2009 the company entered the biotechnology area, which increasingly required the support of computational services. In addition to bioinformatics services, Ylichron has started providing advanced biotechnology services (DNA sequencing using Sanger and NGS methods). Considering that the biotechnological area has grown significantly, Ylichron has decided to spin off the biotechnological services by inserting them (and enhancing them) in a new company, called Genechron Srl, which is entirely focused on biotechnologies and which has maintained a strong focus on innovation of the company of origin.
Genechron Srl has acquired new partners through an investment round that has allowed public and private investors to join the company; among these, Lazio Innova SpA, an in-house company of the Lazio Region dedicated to the financial support of the industrial sectors of the region, in its role as Venture Capital. Genechron’s Business Plan, in addition to planning a notable growth in the medical diagnostics area (the company will request authorization from the Lazio Region in order to be able to act as a diagnostic center for genetic analyses), is strongly oriented towards the discovery and creation of innovative assays for the quantification of RNA biomarkers, both for diagnostic and pharmaceutical applications.
Genechron has been certified ISO9001:2015 by Bureau Veritas Italia S.p.A. as Genechron’s management system has been evaluated and found to comply with the requirements of the management system standard in the field of molecular genetics and laboratory diagnostic services.
For further information, consult the certificate and the QR code contained in it.